Find policies, billing codes, payers, states, and providers
HCPCS G0659: Definitive Drug Identification Testing (GC/MS, LC/MS)
HCPCS Level II code G0659 represents definitive laboratory drug testing using instrumental methods such as GC/MS or LC/MS that can identify individual drugs and distinguish structural isomers, performed without method- or drug-specific calibration or universal internal standards. It matters nationally because definitive toxicology testing is central to clinical toxicology, substance use disorder evaluation, forensic confirmation, and complex clinical decision-making where initial immunoassay results require confirmation or where isomer differentiation affects treatment or legal outcomes. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. This publication summarizes coding definitions, typical clinical contexts and sites of service, payer considerations, and service-level benchmarking where available. Readers will learn the clinical scope of G0659, how it differs from immunoassay and calibrated mass-spectrometry procedures, common laboratory settings where it is performed, and what to expect in coverage and billing workflows. Data not available in the input is noted where applicable, including detailed payer-specific coverage policies, associated taxonomies, and linked ICD-10 diagnosis usage. The focus is national: this resource clarifies coding intent and operational characteristics to support accurate claim submission and administrative planning.
Customize your policy alerts
Sign up for hcpcs G0659 policy alerts
Get alerted when payer policies referencing G0659 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code G0659 describes a definitive drug test that employs instrumental methods capable of identifying individual drugs and distinguishing structural isomers (for example, GC/MS or LC/MS, single or tandem). The code explicitly excludes immunoassays and simple enzymatic methods and applies when testing is performed without method- or drug-specific calibration, without matrix-matched quality control materials, or without use of stable isotope or other universally recognized internal standards for each analyte per specimen. The service may be reported for qualitative or quantitative results and includes specimen validity testing. Service type: Definitive drug identification testing (laboratory diagnostic service). Typical site of service: Clinical laboratory or other laboratory testing facility where instrumental analytical chemistry (GC/MS, LC/MS) is performed.